SeaSpine Investor Update
$
15-18%
3-year Revenue CAGR
om
150BPS
Commission Leverage
by 2024 (vs. 2019)
S
$300-
$320M
Annual Revenue Threshold
for Adj. EBITDA Breakeven
(exiting 2024)
10%
R&D Expense as % of
Total Revenue in 2024
Q
>500BPS
Adj. GM % Expansion by 2024
$
>50%
Reduction in
Free Cash Flow Burn by 2024
Ⓒ2022 SeaSpine Orthopedics Corporation. All rights reserved | 22
Guidance
Long-Term
Financial guidance information is as of August 2, 2022, based on guidance
provided by SeaSpine leadership on that date. Inclusion of this information in
this presentation is not a confirmation or an update of, and should not be
construed or otherwise assumed to reflect any confirmation or update of, that
guidance by SeaSpine leadership as of any date other than August 2, 2022.
SeaSpineView entire presentation